A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months to < 9 Years.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Study Site
-
-
Queensland
-
Brisbane, Queensland, Australia, 4006
- Study Site
-
-
South Australia
-
North Adelaide, South Australia, Australia, 5006
- Study Site
-
-
Victoria
-
Carlton, Victoria, Australia, 3010
- Study Site
-
-
Western Australia
-
Subiaco, Western Australia, Australia, 6027
- Study Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged >= 6 months to < 9 years at the time of the first study vaccination.
- For children < 3 years of age at the time of first vaccination, born at or after 36 weeks of gestation.
Exclusion Criteria:
- Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study Vaccine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CSL425 (15 mcg)
15 mcg of hemagglutinin antigen per dose.
0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
|
CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
|
|
Experimental: CSL425 (30 mcg)
30 mcg of hemagglutinin antigen per dose.
0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
|
CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Haemagglutination Inhibition (HI) Antibody Titre Seroconversion Rate After the First Vaccination
Time Frame: Before and 21 days after the first vaccination
|
HI antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination HI antibody titre of 1:40 or more; or participants with a pre-vaccination HI titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.
|
Before and 21 days after the first vaccination
|
|
HI Antibody Titre Seroconversion Rate After the Second Vaccination
Time Frame: Before and 21 days after the second vaccination
|
HI antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination HI antibody titre of 1:40 or more; or participants with a pre-vaccination HI titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.
|
Before and 21 days after the second vaccination
|
|
Geometric Mean Fold Increase (GMFI) in the HI Antibody Titre After the First Vaccination
Time Frame: Before and 21 days after the first vaccination
|
GMFI in HI antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.
|
Before and 21 days after the first vaccination
|
|
GMFI in the HI Antibody Titre After the Second Vaccination
Time Frame: Before and 21 days after the second vaccination
|
GMFI in HI antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.
|
Before and 21 days after the second vaccination
|
|
Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the First Vaccination
Time Frame: 21 days after the first vaccination
|
21 days after the first vaccination
|
|
|
Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination
Time Frame: 21 days after the second vaccination
|
21 days after the second vaccination
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)
Time Frame: Up to 180 days after the last vaccination
|
An AESI was defined as an AE for which the association with seasonal influenza vaccine was unclear.
A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).
|
Up to 180 days after the last vaccination
|
|
Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Vaccination
Time Frame: During the 7 days after each vaccination
|
Solicited AEs included AEs that were specifically sought for.
Grade 3 solicited AE definitions: Cried when limb was moved/spontaneously painful (Cohort A) or prevented normal daily activities (Cohort B) for injection site pain; Size > 100 mm for injection site redness and induration/swelling; Temperature > 103.1°F (39.5°C) for fevers; Prevented normal daily activities or required medical intervention for all other systemic AEs.
|
During the 7 days after each vaccination
|
|
Duration of Solicited AEs After the First Vaccination
Time Frame: During the 7 days after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7.
|
Solicited AEs included AEs that were specifically sought for.
|
During the 7 days after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7.
|
|
Duration of Solicited AEs After the Second Vaccination
Time Frame: During the 7 days after the second vaccination and up to Day 20 after the second vaccination if AE was ongoing at Day 7.
|
Solicited AEs included AEs that were specifically sought for.
|
During the 7 days after the second vaccination and up to Day 20 after the second vaccination if AE was ongoing at Day 7.
|
|
Frequency and Intensity of Unsolicited Adverse Events After the First or Second Vaccination
Time Frame: During the 21 days after each vaccination; up to 180 days after the last vaccination for SAEs, AESIs, and NOCIs
|
Unsolicited AEs included AEs other than those specifically sought for.
Grade 1 unsolicited AE definition: Easily tolerated and did not interfere with normal daily activities.
Grade 2 unsolicited AE definition: Some interference with normal daily activities.
Grade 3 unsolicited AE definition: Prevented normal daily activities.
|
During the 21 days after each vaccination; up to 180 days after the last vaccination for SAEs, AESIs, and NOCIs
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Director Vaccines, Seqirus
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CSLCT-CAL-09-60
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.